Drug Trial Radar · NCT01492101
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Last checked: Nov 19, 2026Latest source record: Jun 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
852
Actual
Start
Dec 2011
Primary completion
Apr 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- Nektar TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.
Conditions
- Locally Recurrent Breast Cancer
- Metastatic Breast Cancer
Interventions
NKTR-102Drug
145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
Treatment of Physician's Choice (TPC)Drug
One of the following Treatment of Physician Choice will be administered per standard of care: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Kaplan-Meier Estimate of Overall Survival: Intention to Treat (ITT) PopulationTime frame: 36 Months
Locations
153 sites in 11 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC - NAHOA
Flagstaff, Arizona
Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center
Burbank, California
University of Southern California
Los Angeles, California
PMK Medical Group, Inc., DBA Ventura County Hematology Oncology Specialists
Oxnard, California
Wilshire Oncology Medical Group, Inc.
Pasadena, California
Desert Hematology Oncology Medical Group
Rancho Mirage, California
University of California San Francisco
San Francisco, California
Stanford University School of Medicine
Stanford, California
Kaiser Permanente
Vallejo, California
Rocky Mountain Cancer Centers
Denver, Colorado
Pre clinical Science Bldg LR3
Washington D.C., District of Columbia
Medstar
Washington D.C., District of Columbia
Mayo Clinic in Florida
Jacksonville, Florida
University of Miami School of Medicine
Miami, Florida
Advanced Medical Specialties
Miami, Florida
Florida Cancer Research Institute
Plantation, Florida
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida
Northeast Georgia Cancer Care
Athens, Georgia
Peachtree Hematology Oncology Consultants
Atlanta, Georgia
Emory University
Atlanta, Georgia
Central Georgia Cancer Care
Macon, Georgia
Northwest Georgia Oncology Centers, P.C.
Marietta, Georgia
Summit Cancer Care, P.C.
Savannah, Georgia
The University of Chicago Medicine
Chicago, Illinois
Oncology Specialists
Niles, Illinois
Illinois Cancer Care, P.C.
Peoria, Illinois
IU Health Simon Cancer Center
Indianapolis, Indiana
Hall-Perrine Cancer Center, 3rd Floor
Cedar Rapids, Iowa
Kansas City Cancer Center
Overland Park, Kansas
Louisville Oncology Clinical Research Program
Louisville, Kentucky
Maryland Oncology Hematology, P.A.
Columbia, Maryland
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Coborn Cancer Center
Saint Cloud, Minnesota
Missouri Cancer Associates
Columbia, Missouri
Washington University in St. Louis
St Louis, Missouri
Missouri Baptist Medical Center
St Louis, Missouri
Frontier Cancer Center and Blood Institute
Billings, Montana
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.